{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:00:39Z","timestamp":1777118439881,"version":"3.51.4"},"reference-count":61,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>The hiccup (Latin singultus) is an involuntary periodic contraction of the diaphragm followed by glottic closure, which can be a rare side effect of aripiprazole. In contrast to the structurally closely related aripiprazole, brexpiprazole was not associated with this particular adverse drug reaction. Having two very similar drugs that differ in their ability to induce hiccups represents a unique opportunity to gain insight into the receptors involved in the pathophysiology of the symptom and differences in clinical effects between aripiprazole and brexpiprazole. The overlap between maneuvers used to terminate paroxysmal supraventricular tachycardia and those employed to terminate bouts of hiccups suggests that activation of efferent vagal fibers can be therapeutic in both instances. Recent work seems to support a pivotal role for serotonin receptors in such vagal activation. It is unlikely that a unique receptor-drug interaction could explain the different effects of the examined drugs on hiccup. The different effect is most likely the consequence of several smaller effects at more than one receptor. Brexpiprazole is a highly affine (potent) \u03b12\u2062C antagonist and, therefore, also an indirect 5-HT1\u2062A agonist. In contrast, aripiprazole is a partial 5-HT1\u2062A agonist (weak antagonist) and an HT3 antagonist. Activation of 5-HT1\u2062A receptors enhances vagal activity while HT3 blockade reduces it. Vagus nerve activation is therapeutic for hiccups. A definitive answer continues to be elusive.<\/jats:p>","DOI":"10.31083\/j.jin.2021.01.273","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T08:54:59Z","timestamp":1617353699000},"source":"Crossref","is-referenced-by-count":4,"title":["The action of aripiprazole and brexpiprazole at the receptor level in singultus"],"prefix":"10.31083","volume":"20","author":[{"given":"Eman","family":"Alefishat","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine and Health Science, Khalifa University of Science and Technology, 127788 Abu Dhabi, United Arab Emirates"},{"name":"Center for Biotechnology, Khalifa University of Science and Technology, 127788 Abu Dhabi, United Arab Emirates"},{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, 11941 Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujain","family":"Aloum","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine and Health Science, Khalifa University of Science and Technology, 127788 Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidiu C","family":"Baltatu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine and Health Science, Khalifa University of Science and Technology, 127788 Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg A","family":"Petroianu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine and Health Science, Khalifa University of Science and Technology, 127788 Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref1","unstructured":"Petroianu G. Hiccups in: Conn\u2019s current therapy (pp. 27-29). Philadelphia, PA: Elsevier Saunders. 2019."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Behere RV, Venkatasubramanian G, Naveen MN, Gangadhar BN. Aripiprazole-induced hyponatremia. The Journal of Clinical Psychiatry. 2007; 68: 640-641.","DOI":"10.4088\/JCP.v68n0423g"},{"key":"ref3","unstructured":"Ginsberg D. Aripiprazole-induced hyponatremia. Primary Psychiatry 2007; 14: 19-20."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ray P, Zia Ul Haq M, Nizamie SH. Aripiprazole-induced hiccups: a case report. General Hospital Psychiatry. 2009; 31: 382-384.","DOI":"10.1016\/j.genhosppsych.2008.09.014"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kattura R, Shet P. Aripiprazole induced hiccups. Mental Health Clinician. 2013; 3: 119-121.","DOI":"10.9740\/mhc.n166817"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kutuk MO, Tufan AE, Guler G, Yildirim V, Toros F. Persistent hiccups due to aripiprazole in an adolescent with obsessive compulsive disorder responding to dose reduction and rechallenge. Oxford Medical Case Reports. 2016; 2016: 66-67.","DOI":"10.1093\/omcr\/omw017"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Caloro M, Pucci D, Calabr\u00f2 G, de Pisa E, Mancinelli I, Rosini E, et al. Development of hiccup in male patients hospitalized in a psychiatric ward. Clinical Neuropharmacology. 2016; 39: 67-72.","DOI":"10.1097\/WNF.0000000000000129"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Sakalli Kani A, \u00d6cek T, Aksoy-Poyraz C, Turan S, Duran A. Aripiprazole-induced acute hiccups: a case report. The Journal of Neuropsychiatry and Clinical Neurosciences. 2015; 27: e60.","DOI":"10.1176\/appi.neuropsych.13100307"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"De Filippis S, Ranieri V, Cuomo I, Zingaretti P, Kotzalidis GD, Telesforo CL, et al. Hiccup with aripiprazole plus benzodiazepines resolving with pregabalin and\/or benzodiazepine switch\/discontinuation. Journal of Clinical Psychopharmacology. 2015; 35: 195-197.","DOI":"10.1097\/JCP.0000000000000292"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mathews M, Mathews N, Menon N, Ahmad R, Papa-Molter A. Hiccups with dose titration of aripiprazole. The Primary Care Companion for CNS Disorders. 2019; 20.","DOI":"10.4088\/PCC.17l02251"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Serafini G, Piccinini G, Visimberga S, Cervetti A, Belvederi Murri M, Monacelli F, et al. Aripiprazole-induced persistent hiccup: a case report and review of the literature. Psychiatria Danubina. 2019; 31: 19-26.","DOI":"10.24869\/psyd.2019.26"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yeh Y. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy. Clinical Neuropharmacology. 2011; 34: 135-136.","DOI":"10.1097\/WNF.0b013e31822046bc"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Duvarci \u0130, Yilmaz M. Persistent hiccups after switching from zuclopenthixol to aripiprazole. Klinik Psikofarmakoloji B\u00fcLteni-Bulletin of Clinical Psychopharmacology. 2013; 23: 89-90.","DOI":"10.5455\/bcp.20120419125722"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hori H, Nakamura J. Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia. Clinical Neuropharmacology. 2014; 37: 88-89.","DOI":"10.1097\/WNF.0000000000000032"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Silverman MA, Leung JG, Schak KM. Aripiprazole-associated hiccups. Journal of Pharmacy Practice. 2014; 27: 587-590.","DOI":"10.1177\/0897190014544797"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Das S, Barnwal P, Winston A B, Mondal S, Saha I. Brexpiprazole: so far so good. Therapeutic Advances in Psychopharmacology. 2016; 6: 39-54.","DOI":"10.1177\/2045125315614739"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015; 29: 773-799.","DOI":"10.1007\/s40263-015-0278-3"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectrums. 2016; 21: 1-6.","DOI":"10.1017\/S1092852915000954"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999; 20: 612-627.","DOI":"10.1016\/S0893-133X(98)00099-2"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clinical Pharmacokinetics. 2018; 57: 1493-1528.","DOI":"10.1007\/s40262-018-0664-3"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Wang J, Zhu H, Donovan JL, Yuan H, Markowitz JS, Geesey ME, et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophrenia Research. 2009; 110: 90-94.","DOI":"10.1016\/j.schres.2009.01.011"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Huang S, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clinical Pharmacology and Therapeutics. 2007; 81: 298-304.","DOI":"10.1038\/sj.clpt.6100054"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. The Journal of Pharmacology and Experimental Therapeutics. 2014; 350: 589-604.","DOI":"10.1124\/jpet.114.213793"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. Journal of Pharmacology and Experimental Therapeutics. 2014; 351: 585-595.","DOI":"10.1124\/jpet.114.218578"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Oosterhof CA, Mansari ME, Bundgaard C, Blier P. Brexpiprazole alters monoaminergic systems following repeated administration: an in vivo electrophysiological study. International Journal of Neuropsychopharmacology. 2016; 19: pyv111.","DOI":"10.1093\/ijnp\/pyv111"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic Advances in Psychopharmacology. 2017; 7: 29-41.","DOI":"10.1177\/2045125316672136"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28: 1400-1411.","DOI":"10.1038\/sj.npp.1300203"},{"key":"ref28","unstructured":"Glennon RA. Serotonin receptors and site-selective agents. Journal of Physiology and Pharmacology. 1991; 42: 49-60."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry and Clinical Neurosciences. 2015; 69: 243-258.","DOI":"10.1111\/pcn.12242"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28: 519-526.","DOI":"10.1038\/sj.npp.1300027"},{"key":"ref31","unstructured":"Glennon RA, Dukat M. Serotonin receptors and drugs affecting serotonergic neurotransmission (Chapter 14). 5-HT6 receptors and agents. In: Foye\u2019s Principles of Medicinal Chemistry. Sixth edition. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins. 2008."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Abbas AI, Hedlund PB, Huang X, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009; 205: 119-128.","DOI":"10.1007\/s00213-009-1521-8"},{"key":"ref33","unstructured":"Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. The Journal of Pharmacology and Experimental Therapeutics. 1994; 268: 1403-1410."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Di Giovanni G, Svob Strac D, Sole M, Unzeta M, Tipton KF, M\u00fcck-\u0160eler D, et al. Monoaminergic and histaminergic strategies and treatments in brain diseases. Frontiers in Neuroscience. 2019; 10: 541.","DOI":"10.3389\/fnins.2016.00541"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Zhou M, Engel K, Wang J. Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochemical Pharmacology. 2007; 73: 147-154.","DOI":"10.1016\/j.bcp.2006.09.008"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkholm C, Marcus MM, Konradsson-Geuken A, Jardemark K, Svensson TH. The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. European Neuropsychopharmacology. 2017; 27: 411-417.","DOI":"10.1016\/j.euroneuro.2017.01.014"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Boyd KN, Mailman RB. Dopamine receptor signaling and current and future antipsychotic drugs. Current Antipsychotics. 2012; 53-86.","DOI":"10.1007\/978-3-642-25761-2_3"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Ginovart N, Kapur S. Dopamine receptors and the treatment of schizophrenia. The Dopamine Receptors. 2010; 2: 431-477.","DOI":"10.1007\/978-1-60327-333-6_16"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Soto M, Bonifazi A, Cai NS, Ellenberger MP, Newman AH, Ferr\u00e9 S, et al. Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist. Molecular Pharmacology. 2016; 89: 457-466.","DOI":"10.1124\/mol.115.101808"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Newman-Tancredi A, Assi\u00e9 M, Leduc N, Ormi\u00e8re A, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1a receptors: affinity, efficacy and potential implications for treatment of schizophrenia. the International Journal of Neuropsychopharmacology. 2005; 8: 341-356.","DOI":"10.1017\/S1461145704005000"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Castro-Hern\u00e1ndez J, Afonso-Oramas D, Cruz-Muros I, Salas-Hern\u00e1ndez J, Barroso-Chinea P, Moratalla R, et al. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Neurobiology of Disease. 2015; 74: 325-335.","DOI":"10.1016\/j.nbd.2014.12.007"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Tuplin EW, Holahan MR. Aripiprazole, a drug that displays partial agonism and functional selectivity. Current Neuropharmacology. 2017; 15: 1192-1207.","DOI":"10.2174\/1570159X15666170413115754"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Berg KA, Clarke WP. Making sense of pharmacology: inverse agonism and functional selectivity. International Journal of Neuropsychopharmacology. 2018; 21: 962-977.","DOI":"10.1093\/ijnp\/pyy071"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. [D-Arg1,D-Phe5,D-Trp7,9,Leu11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. The Journal of Biological Chemistry. 1998; 273: 3097-3104.","DOI":"10.1074\/jbc.273.5.3097"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, \u201cGoldilocks\u201d actions at dopamine receptors. The Journal of Clinical Psychiatry. 2001; 62: 841-842.","DOI":"10.4088\/JCP.v62n1101"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Browning KN. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Frontiers in Neuroscience. 2015; 9: 413.","DOI":"10.3389\/fnins.2015.00413"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Jordan D. Vagal control of the heart: central serotonergic (5-HT) mechanisms. Experimental Physiology. 2005; 90: 175-181.","DOI":"10.1113\/expphysiol.2004.029058"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Ramage AG, Villal\u00f3n CM. 5-hydroxytryptamine and cardiovascular regulation. Trends in Pharmacological Sciences. 2009; 29: 472-481.","DOI":"10.1016\/j.tips.2008.06.009"},{"key":"ref49","unstructured":"Petroianu G, Brunnengraber R. Wenn Schluckauf zur Plage wird: Gibt es eine rationale Therapie? Pharmazeutische Zeitung. 1992; 137: 1891-1896. (In German)"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Petroianu GA, Lorke DE. The role of serotonin in singultus: a review. Frontiers in Neuroscience. 2020; 14: 629.","DOI":"10.3389\/fnins.2020.00629"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Pithadia A. 5-Hydroxytryptamine receptor subtypes and their modulators with therapeutic potentials. Journal of Clinical Medicine Research. 2009;","DOI":"10.4021\/jocmr2009.05.1237"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7) Journal of Medicinal Chemistry. 2003; 46: 2795-2812.","DOI":"10.1021\/jm030030n"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Berendsen HH, Broekkamp CL. Indirect in vivo 5-HT1a-agonistic effects of the new antidepressant mirtazapine. Psychopharmacology. 1998; 133: 275-282.","DOI":"10.1007\/s002130050402"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Godbout R, Chaput Y, Blier P, de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-i. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology. 1991; 30: 679-690.","DOI":"10.1016\/0028-3908(91)90175-B"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Blier P, Curet O, Chaput Y, de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine (II). Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology. 1991; 30: 691-701.","DOI":"10.1016\/0028-3908(91)90176-C"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Takahashi T, Murata T, Omori M, Tagaya M, Wada Y. Successful treatment of intractable hiccups with serotonin (5-HT)1A receptor agonist. Journal of Neurology. 2005; 251: 486-487.","DOI":"10.1007\/s00415-004-0377-4"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Uys MM, Shahid M, Harvey BH. Therapeutic potential of selectively targeting the alpha2C-adrenoceptor in cognition, depression, and schizophrenia-new developments and future perspective. Frontiers in Psychiatry. 2017; 8: 144.","DOI":"10.3389\/fpsyt.2017.00144"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1997; 124: 57-73.","DOI":"10.1007\/BF02245606"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1a and 5-HT 2a receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology. 2007; 190: 373-382.","DOI":"10.1007\/s00213-006-0621-y"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology. 1997; 321: 105-111.","DOI":"10.1016\/S0014-2999(96)00920-X"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric Disease and Treatment. 2019; 15: 2559-2569.","DOI":"10.2147\/NDT.S209284"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/20\/1\/10.31083\/j.jin.2021.01.273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:18:23Z","timestamp":1732720703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/20\/1\/10.31083\/j.jin.2021.01.273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["1616655662924-470325895"],"URL":"https:\/\/doi.org\/10.31083\/j.jin.2021.01.273","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"article-number":"247"}}